Remove Article Remove Licensing Remove Packaging
article thumbnail

Animals Need Drugs Too, But Not Without CVM Approval

FDA Law Blog: Biosimilars

CVM does not regulate the practice of veterinary medicine (that’s a state licensing board) or vaccines for animal diseases (that’s USDA). Palmer & Riëtte van Laack — Most of us love our furry friends, and with the boom in pet ownership during the pandemic, it is no surprise that the market for pet products has become enormous.

Drugs 59
article thumbnail

The Beginner’s Guide to Playwright Setup

Perficient: Drug Development

package.json and package-lock.json : These files are created to manage dependencies and package information for your project. package-lock.json is automatically generated and ensures consistent and reproducible installations of the specified packages. It supports programming languages like NodeJS, Java, C#, and Python.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You CDER’s latest novel drug approvals report shows how the pandemic is still affecting some drug approvals

Agency IQ

These windows depend on whether the new drug application (NDA) or biologics license application (BLA) is a new molecular entity, and if the application has received standard review (10 months, plus 2 months of administrative time) or priority review (6 months, plus 2 months of administrative time).

FDA 40
article thumbnail

Making Sense of Sitecore’s Headless Options

Perficient: Drug Development

If you read my last article, the big deal with headless , you know that the big deal is performance. Implementing Experience Edge requires additional licensing beyond the standard Sitecore licensing, reflecting the added performance enhancements it offers. The architecture you get leveraging a headless architecture with Next.js

article thumbnail

Article EMA Thank You EMA’s 2023 new medicines report suggests return to pre-pandemic volume

Agency IQ

approval and discussion with the FDA, the company announced in December 2023 that it intends to re-submit the biologics license application in the U.S. The clinical package, safety and label were not affected. Based on the E.U. Ebglyss (lebrikizumab; Almirall) received a Complete Response Letter (CRL) from the U.S. FDA in October 2023.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

Q: What is the typical time period between the submission of the briefing package and the pre-IND meeting? A: The FDA’s guidance document indicates the briefing package is submitted four weeks before the meeting. Q: The speaker just stated that the Meeting Package is due 60 days before the meeting date.

article thumbnail

Article EMA Thank You New MHRA Windsor Framework documents guide post-Brexit flow of medicines for U.K., Great Britain, and the E.U.

Agency IQ

The document specifically notes that it applies to “medicinal products for human use intended to be placed on the market in Northern Ireland in accordance with Article 6 of Directive 2001/83/EC,” the current European pharmaceutical legislation. Article 54(o) of the existing E.U. Definitions from the existing E.U.